report adjust ep consensu
expect estim better-than-anticip revenu
primari differ versu adjust ep forecast
million well consensu expect
million estim million adjust result
adopt account standard codif lower
report revenu sg expens approxim million
revenu growth would exclud acquisit
chang foreign currenc exchang rate syk sale improv
organ forecast repres
compani best perform decad quarter syk organ
growth led strength medsurg equip organ
versu estim orthoped product primarili consist
mako robot surgeri system bone cement
organ improv perform trauma extrem
adjust result adopt syk adjust
oper margin improv bp year-over-year
slightli estim within five-year target rang
bp annual adjust oper margin expans despit initi dilut
group acquisit
expect adjust ep versu prior consensu
expect addit compani anticip organ
growth bp adjust oper margin expans
despit dilut acquisit particularli regard organ
growth point robust order backlog capit equip product
enter strong year new product launch includ
high definit camera system endoscopi schedul roll
end factor contribut best organ growth guidanc
start year decad furthermor note exceed top
end initi organ growth guidanc past four year
rais adjust ep estim
primarili reflect higher revenu assumpt new adjust
ep forecast
total debt total asset
deliv anoth quarter significantli better-than-expect organ
growth upsid consensu adjust ep estim moreov compani
start see greater benefit transform growth
program give us increas confid compani achiev least
bp adjust oper margin expans despit headwind
acquisit overal remain posit long-term outlook
maintain buy rate new price target
import pleas read disclosur disclaim page report
report adjust ep consensu expect estim
better-than-anticip revenu primari differ versu adjust ep forecast
stryker adjust incom statement analysisnorthcoast research million except percentag per share sg interest incom incom margin incom trauma sustain compani report northcoast research estim factset result reflect adopt account standard codif lower report revenu sg expens million report basi syk revenu increas year-over-year million well
consensu expect million estim million adjust result
adopt account standard codif lower report revenu sg
expens approxim million revenu growth would exclud acquisit
chang foreign currenc exchang rate syk sale improv organ
forecast repres compani best perform decad
divis standpoint strong result syk medsurg equip divis drove upsid
organ growth forecast compani orthoped product sale also better anticip
medsurg equip achiev organ growth forecast
quarter result strong across divis three larg segment led low-double-digit organ growth
medic instrument high-single-digit organ growth instrument adjust invuiti
safeair ag acquisit rel estim strength medic biggest surpris given
tough double-digit year-over-year growth comparison core medic busi hospit bed
stretcher surfac physio-control quarter howev two segment product
easi comp last year suppli issu deliv double-digit organ growth
stryker corporationtot compani organ growth analysi two fewer sale day year-over-year one extra sale day year-over-year one fewer sale day year-over-year compani report corpor organ growth analysiscategorynorthcoastreportedtot compani organ orthoped medsurg equip neurotechnolog spine compani report northcoast research estim
orthoped product syk sale increas organ estim
compani combin hip knee implant sale slightli forecast off-set
strength orthoped product primarili mako robot surgeri system bone cement well
rebound trauma extrem organ growth compani move past product suppli issu
notabl organ growth orthoped product except strong mako
robot surgeri system placement increas
knee implant achiev organ growth well market rate rel
strong tough prior year comparison quarter syk knee implant organ growth
organ benefit increas demand cementless triathlon tritanium knee system use
compani domest knee implant case addit mako system sale competit account
increas surgeon train mako total knee implant applic roughli versu
approxim syk earn call total case perform syk mako
total knee
hip implant achiev organ growth strong result unit state somewhat
off-set weaker perform intern overal encourag syk hip result compani
expect hip organ growth improv next year despit focu sale forc key
differenti knee mako total knee applic cementless knee offer
neurotechnolog spine product achiev organ growth
forecast neurotechnolog sale growth slow modestli remain double-digit rang spine
result larg consist forecast notabl encourag syk expect mid-
single-digit pro forma organ growth spine busi includ group earli comment
regard group integr effort
stryker corporationworldwid hip implant organ growth analysi two fewer sale day year-over-year one extra sale day year-over-year one fewer sale day year-over-yearsourc compani report corporationneurotechnolog spine organ growth analysissourc compani report two fewer sale day year-over-year one extra sale day year-over-year one fewer sale day adjust result adopt syk adjust oper margin improv
bp year-over-year slightli estim within five-year target rang
bp annual adjust oper margin expans despit initi dilut group acquisit
quarter syk adjust gross margin declin bp year-over-year reflect product mix
primarili strength sale medsurg equip carri corpor averag gross margin
similar oper margin overal busi neg price growth year-over-year
howev off-set lower adjust sg expens reflect benefit
transform growth initi expens
expect adjust ep versu prior consensu expect addit
compani anticip organ growth bp adjust oper margin expans
despit dilut acquisit particularli regard organ growth point robust
order backlog capit equip product enter strong year new product launch
includ high definit camera system endoscopi schedul roll end
factor contribut best organ growth guidanc start year decad furthermor note
exceed top end initi organ growth guidanc past four year
rais adjust ep estim primarili reflect higher revenu
assumpt new adjust ep forecast
summari deliv anoth quarter significantli better-than-expect organ growth upsid
consensu adjust ep estim moreov compani start see greater benefit
transform growth program give us increas confid compani achiev least bp
adjust oper margin expans despit headwind acquisit overal remain
posit long-term outlook maintain buy rate new price target
stryker corporationannu incom statement analysi adjust northcoast research million except percentag per share gross gross sg intang oper oper net interest incom incom tax incom extra incom extra extra net net wghd com share ep ep growth ep growth start exclud acquistion-rel intang amort expens adjust ep compani report northcoast research estim disclosur
